Trials / Completed
CompletedNCT00345319
Purified Rabies Vaccine for Human Use (Chick-embryo Cell)
Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 630 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 10 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | rabies vaccine | Administration of PCECV according to ESSEN regimen |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2006-06-28
- Last updated
- 2011-12-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00345319. Inclusion in this directory is not an endorsement.